metformin has been researched along with Hypomenorrhea in 32 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 9.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| " Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of type 2 diabetes mellitus." | 8.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| "To review the use of the insulin-sensitizing agent metformin in women with polycystic ovary syndrome (PCOS)." | 8.81 | Use of metformin in polycystic ovary syndrome. ( De Sloover Koch, Y; Ernst, ME, 2001) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 6.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 6.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "The aim of this study was to compare the effectiveness of myo-inositol (MYO) and metformin, in monotherapy or in association with recombinant follicle stimulating hormone (r-FSH), in the treatment of menstrual irregularities, chronic anovulation, and female infertility in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. ( Benedetto, V; Raffone, E; Rizzo, P, 2010) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 5.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| " Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of type 2 diabetes mellitus." | 4.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| "To review the use of the insulin-sensitizing agent metformin in women with polycystic ovary syndrome (PCOS)." | 4.81 | Use of metformin in polycystic ovary syndrome. ( De Sloover Koch, Y; Ernst, ME, 2001) |
| "To characterize girls with irregular menses and effects of glycemic treatments on menses and sex steroids in the Treatment Options for Type 2 Diabetes in Youth (TODAY) study." | 2.87 | Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. ( Arslanian, SA; Braffett, BH; Caprio, S; Geffner, ME; Kelsey, MM; Levitsky, LL; McKay, SV; Shah, R; Sprague, JE, 2018) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 2.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 2.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin was less effective than the OCP in improving menstrual pattern (Peto odds ratio (OR) 0." | 2.44 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. ( Costello, M; Eden, J; Johnson, N; Shrestha, B; Sjoblom, P, 2007) |
| "Polycystic ovary syndrome is a diagnosis of exclusion of other causes of hyperandrogenism." | 2.43 | Polycystic ovary syndrome--a management update. ( Costello, MF, 2005) |
| "Metformin is an appropriate medical option to improve ovulation rates for women who cannot take combined hormone contraception or whom are attempting conception." | 1.62 | Menstrual Dysfunction in PCOS. ( Decherney, AH; Saunders, R; Walker, K, 2021) |
| "To compare the incidence of gestational diabetes mellitus (GDM) in Iranian infertile women with polycystic ovary syndrome (PCOS) and women without PCOS after pregnancies resulting from either assisted reproductive technology (ART) or spontaneous as well as to determine the risk factors of GDM in PCOS women." | 1.40 | Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). ( Arabipoor, A; Ashrafi, M; Hosseini, R; Nourbakhsh, F; Sheikhan, F; Zolfaghari, Z, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 19 (59.38) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Garzia, E | 1 |
| Galiano, V | 1 |
| Marfia, G | 1 |
| Navone, S | 1 |
| Grossi, E | 1 |
| Marconi, AM | 1 |
| Manique, MES | 1 |
| Ferreira, AMAP | 1 |
| DiVall, SA | 1 |
| Walker, K | 1 |
| Decherney, AH | 1 |
| Saunders, R | 1 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Lepine, S | 1 |
| Jo, J | 1 |
| Metwally, M | 1 |
| Cheong, YC | 1 |
| Kelsey, MM | 1 |
| Braffett, BH | 1 |
| Geffner, ME | 1 |
| Levitsky, LL | 1 |
| Caprio, S | 1 |
| McKay, SV | 1 |
| Shah, R | 1 |
| Sprague, JE | 1 |
| Arslanian, SA | 1 |
| Ibáñez, L | 1 |
| Ong, KK | 1 |
| López-Bermejo, A | 1 |
| Dunger, DB | 1 |
| de Zegher, F | 1 |
| Conway, G | 1 |
| Dewailly, D | 1 |
| Diamanti-Kandarakis, E | 2 |
| Escobar-Morreale, HF | 1 |
| Franks, S | 1 |
| Gambineri, A | 1 |
| Kelestimur, F | 1 |
| Macut, D | 1 |
| Micic, D | 1 |
| Pasquali, R | 1 |
| Pfeifer, M | 1 |
| Pignatelli, D | 1 |
| Pugeat, M | 1 |
| Yildiz, B | 1 |
| Ashrafi, M | 1 |
| Sheikhan, F | 1 |
| Arabipoor, A | 1 |
| Hosseini, R | 1 |
| Nourbakhsh, F | 1 |
| Zolfaghari, Z | 1 |
| Powers, SE | 1 |
| Uliassi, NW | 1 |
| Sullivan, SD | 1 |
| Tuchman, LK | 1 |
| Mehra, R | 1 |
| Gomez-Lobo, V | 1 |
| Spritzer, PM | 1 |
| Motta, AB | 1 |
| Sir-Petermann, T | 1 |
| Al-Zubeidi, H | 1 |
| Klein, KO | 1 |
| Sokhal, D | 1 |
| Kraus, C | 1 |
| Goodman, NF | 1 |
| Cobin, RH | 1 |
| Futterweit, W | 1 |
| Glueck, JS | 1 |
| Legro, RS | 1 |
| Carmina, E | 1 |
| Kulshreshtha, B | 1 |
| Arora, A | 1 |
| Pahuja, I | 1 |
| Sharma, N | 1 |
| Pant, S | 1 |
| Al Khalifah, RA | 1 |
| Florez, ID | 1 |
| Dennis, B | 1 |
| Thabane, L | 1 |
| Bassilious, E | 1 |
| Palomba, S | 1 |
| Falbo, A | 1 |
| Zullo, F | 1 |
| Orio, F | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Raffone, E | 1 |
| Rizzo, P | 1 |
| Benedetto, V | 1 |
| Genazzani, AD | 1 |
| Ricchieri, F | 1 |
| Lanzoni, C | 1 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Raval, AD | 1 |
| Hunter, T | 1 |
| Stuckey, B | 1 |
| Hart, RJ | 1 |
| Bates, GW | 1 |
| Propst, AM | 1 |
| Barbieri, RL | 1 |
| Gargiulo, AR | 1 |
| Kriplani, A | 1 |
| Agarwal, N | 1 |
| Costello, MF | 2 |
| Costello, M | 1 |
| Shrestha, B | 2 |
| Eden, J | 2 |
| Sjoblom, P | 2 |
| Johnson, N | 1 |
| Johnson, NP | 1 |
| Moghetti, P | 1 |
| Castello, R | 1 |
| Negri, C | 1 |
| Tosi, F | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Zanolin, E | 1 |
| Muggeo, M | 1 |
| Taylor, AE | 1 |
| De Sloover Koch, Y | 1 |
| Ernst, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| Pilot Study on the Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic[NCT05196568] | 100 participants (Anticipated) | Interventional | 2021-07-01 | Active, not recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
15 reviews available for metformin and Hypomenorrhea
| Article | Year |
|---|---|
Practical considerations for diagnosis and treatment of polycystic ovary syndrome in adolescence - distilling guidelines into clinical practice.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformi | 2023 |
Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
Topics: Acne Vulgaris; Clomiphene; Female; Gonadotropins; Hirsutism; Humans; Laparoscopy; Letrozole; Menstru | 2017 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis.
Topics: Acne Vulgaris; Adolescent; Body Mass Index; Contraceptives, Oral; Female; Glucose Metabolism Disorde | 2016 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Use of metformin in the treatment of polycystic ovary syndrome.
Topics: Adaptation, Psychological; Body Mass Index; Endocrine System; Female; Humans; Hyperandrogenism; Hypo | 2010 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2011 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
Polycystic ovary syndrome--a management update.
Topics: Contraceptives, Oral; Family Practice; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inf | 2005 |
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Topics: Acne Vulgaris; Cardiovascular Diseases; Contraceptives, Oral, Combined; Endometrial Neoplasms; Femal | 2007 |
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
Topics: Acne Vulgaris; Adult; Cardiovascular Diseases; Contraceptives, Oral, Combined; Female; Hirsutism; Hu | 2007 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
Use of metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome | 2001 |
7 trials available for metformin and Hypomenorrhea
| Article | Year |
|---|---|
Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.
Topics: Adult; Biomarkers, Pharmacological; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Ag | 2022 |
Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
Topics: Adolescent; Androgens; Aspartate Aminotransferases; Body Mass Index; Diabetes Mellitus, Type 2; Drug | 2018 |
Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.
Topics: Adolescent; Androgens; Body Mass Index; Child; Chromatography, Liquid; Contraceptives, Oral, Combine | 2015 |
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women.
Topics: Adult; Anovulation; Dietary Supplements; Drug Therapy, Combination; Female; Fertility Agents, Female | 2010 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resist | 2004 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
10 other studies available for metformin and Hypomenorrhea
| Article | Year |
|---|---|
Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformin; Poly | 2022 |
Menstrual Dysfunction in PCOS.
Topics: Female; Humans; Menstruation Disturbances; Metformin; Ovulation; Ovulation Induction; Polycystic Ova | 2021 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire.
Topics: Adult; Androgens; Biomarkers; Clomiphene; Contraceptives, Oral; Diagnosis, Differential; Endocrinolo | 2014 |
Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS).
Topics: Adult; Cross-Sectional Studies; Diabetes, Gestational; Female; Fertilization; Humans; Hypoglycemic A | 2014 |
Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome.
Topics: Adolescent; Adolescent Medicine; Androgens; Child; Contraceptives, Oral; Endocrinology; Female; Gyne | 2015 |
Insulin Sensitizers for Treatment of Menstrual Irregularities Associated with PCOS.
Topics: Comparative Effectiveness Research; Contraceptives, Oral; Evidence-Based Practice; Female; Humans; H | 2015 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine | 2015 |
Menstrual cyclicity post OC withdrawal in PCOS: Use of non-hormonal options.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Menstrual Cy | 2016 |